Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level

In patients with septic shock and high levels of endotoxin in the blood, researchers wondered if adding polymyxin B hemoperfusion to standard treatment would not only dial back the endotoxin activity but also improve clinical outcomes.

In patients with septic shock and high levels of endotoxin in the blood, researchers wondered if adding polymyxin B hemoperfusion to standard treatment would not only dial back the endotoxin activity but also improve clinical outcomes. They assembled a study population of 450 critically ill adults in the United States and Canada who fit the patient profile, randomizing them to usual care plus sham or real polymyxin B hemoperfusion. The main endpoint was 28-day mortality, which was 34.5% with sham hemoperfusion and 37.7% with polymyxin B hemoperfusion. Based on the trial results, the investigators concluded that polymyxin B hemoperfusion did not prolong survival in patients with septic shock and high levels of endotoxin in the blood.